Working… Menu

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03699241
Recruitment Status : Unknown
Verified July 2019 by International AIDS Vaccine Initiative.
Recruitment status was:  Recruiting
First Posted : October 9, 2018
Last Update Posted : July 26, 2019
Fred Hutchinson Cancer Research Center - Seattle HIV Vaccine Trials Unit
Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)
Massachusetts General Hospital
Information provided by (Responsible Party):
International AIDS Vaccine Initiative

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : May 20, 2020
Estimated Study Completion Date : May 20, 2020